Search

Additional file 7: Fig. S4. Allele classification of SNP in cultivated varieties and multiple sequence alignment depicting the amino acid sequence difference of Glyma.16G066600. (a), Represents the genotype distribution of population with SPC less than 42%; (b), Represents the genotype distribution of population with SPC greater than 50%. (c), Represents the multiple sequence alignment depicting the amino acid sequence difference of Glyma.16G066600

Additional file 1: Table S1. Descriptive statistics, broad sense heritability and F-value from ANOVA for SPC in the soybean RIL and F2 population

Additional file 6: Figure S3. Venn diagram analysis for RNA-seq data showing differentially expressed genes (Nanxiadou 25/Rongxiandongdou) at R5, R6, and R7 stages. (a), venn diagram representing the number of up-regulation DEGs. (b), venn diagram representing the number of down-regulation DEGs

Additional file 5: Figure S2. Single nucleotide polymorphism (SNP)-index plots of HP-bulk (High protein bulk) and LP-bulk (Low protein bulk). (a), represent the single nucleotide polymorphism (SNP)-index plots of HP-pool. (b), represent the single nucleotide polymorphism (SNP)-index plots of LP-pool

Additional file 4: Figure S1. Location of quantitative trait loci (QTL) related to protein contents. For simplicity, only show the markers in the QTL confidence intervals, along with the terminal two markers at each end of the QTL-containing chromosomes

Ting Chen, Haiying Wu, Xiuli Chen, Rongrong Xie, Fengyun Wang, Hui Sun, Linqi Chen Department of Endocrinology, Genetics and Metabolism, Children’s Hospital of Soochow University, Suzhou 215000 Jiangsu, People’s Republic of ChinaCorrespondence: Ting ChenDepartment of Endocrinology, Genetics, and Metabolism, Children’s Hospital of Soochow University, Suzhou, Jiangsu, People’s Republic of ChinaTel +86-512-8069-8322Email chenting888@suda.edu.cnStudy Objective: The well-known tumor suppressor transcriptional factor p53 has been proposed to be one of the central hubs of a functionally related and hierarchically arranged gene network coordinating pubertal timing. Our previous studies revealed that p53 is involved in the metabolic control of puberty. The current study aimed to investigate the underlying signaling pathway, through which p53 mediated the metabolic control of puberty.Design, Setting, Participants, Interventions, and Main Outcome Measures: We engineered the expression of p53 and/or Lin28a in GT1-7 cells to investigate the interaction between p53 and Lin28/let-7 system, and their impact on GnRH secretion.Results: Overexpression of p53 stimulated, while inhibition of p53 by pifithrin-α significantly suppressed the GnRH secretion and GPR54 expression levels in response to kisspeptin stimulation in GT1-7 cells. Furthermore, overexpressed p53 suppressed Lin28a and c-Myc expression levels and increased let-7 expression levels in GT1-7 cell lines. On the other hand, inhibition of p53 by pifithrin-α upregulated Lin28a and c-Myc levels and downregulated let-7 expression levels. Moreover, Lin28a overexpression counteracted the effect of p53 overexpression in p53 and Lin28a co-overexpression cells, whose GnRH secretion and GPR54 expression levels were not different from controls. Meanwhile, Lin28a suppression counteracted the effect of pifithrin-α, and the GnRH secretion and GPR54 expression levels are not different from controls in p53 and Lin28a co-suppression cells.Conclusion: These data suggest that p53 is a central mediator of GnRH secretion in hypothalamus, and this effect is at least partly through the Lin28/let-7 pathway.Keywords: pubertal timing, p53, Lin28/let-7 system, gonadotropin-releasing hormone

Liangshun You,1,* Cunying Yao,1,2,* Fan Yang,3 Qing Yang,4 Jianping Lan,5 Xiaolu Song,5 Jianping Shen,6 Xianfu Sheng,6 Xiaohui Chen,7 Huifen Tang,7 Huifang Jiang,8 Haiying Wu,8 Shenxian Qian,3 Haitao Meng1 1Department of Hematology, The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou, People’s Republic of China; 2Department of Hematology, The Second Affiliated Hospital of Anhui Medical University, Hefei, People’s Republic of China; 3Department of Hematology, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China; 4State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou, People’s Republic of China; 5Department of Hematology, Zhejiang Provincial People’s Hospital, Hangzhou, People’s Republic of China; 6Department of Hematology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, People’s Republic of China; 7Department of Hematology, The Affiliated Hospital, Hangzhou Normal University, Hangzhou, People’s Republic of China; 8Department of Hematology, Tongde Hospital of Zhejiang Province, Hangzhou, People’s Republic of China*These authors contributed equally to this workCorrespondence: Haitao Meng; Shenxian Qian Email menghait2004@zju.edu.cn; sxqian@hotmail.comBackground: Candida tropicalis is the most common non-albicans Candida species identified in immunocompromised patients, which often appears with high mortality. However, data on the outcomes of treatment for Candida tropicalis fungemia in patients with neutropenia remain limited.Methods: In the present study, 90 neutropenic adult patients with proven Candida tropicalis fungemia, who received initial antifungal therapy, were retrospectively analyzed.Results: These results revealed that the overall 8-day and 30-day mortality among patients in the entire data set were 22.2% and 33.3%, respectively. However, there was no significant difference between the survival and death group, in terms of baseline characteristics. The univariate analysis of risk factors identified the treatment with azole as a predictor of mortality, while treatments that containing amphotericin B were associated with reduced mortality. In addition, the survival rate on day 30 was observed in 60.7% (17/28) of patients who were initially treated with echinocandins, while this was observed in 86.4% (19/22, P= 0.039) and 100% (13/13, P= 0.024) of patients treated with amphotericin B plus echinocandins and amphotericin B, respectively.Conclusion: These data indicate for the first time that the initial therapy with amphotericin B-based agents was associated with a better survival rate and could be assessed as the optimal strategy for the treatment of Candida tropicalis fungemia in patients with neutropenia.Keywords: Candida tropicalis, candidemia, hematological malignancy, neutropenia, amphotericin B, echinocandins